Abstract
There are over 30 subtypes of non-Hodgkin lymphoma (NHL), each with distinct clinical and pathological features, prognoses, and treatment. Diagnosis of NHLs is made primarily through tissue biopsy. These procedures are invasive and carry risk, in addition to providing limited sampling from one portion of a single tumor lesion. Differentiating between subtypes of NHL can prove to be difficult, and incorrect diagnoses are not uncommon, which leads to delays in appropriate treatment. Thus, there is an unmet clinical need in the field, which we suggest can be improved by clinical implementation of liquid biopsy biomarkers. Liquid biopsies, including analysis of blood plasma for circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles, are an emerging tool for diagnosis of tumors through blood or urine samples. In this review, we discuss the classification and significant features of the various subtypes of NHL, including their pathologic, clinical, and diagnostic criteria, and the latest progress on liquid biopsy biomarkers. The groundwork for studying and applying liquid biopsy biomarkers in non-Hodgkin lymphoma will aid in forming more accurate, less invasive diagnosis, which may ultimately help to guide earlier treatment and decrease disease burden.